Erratum: Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2- (trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S) -2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective Ikur inhibitor (Journal of Medicinal Chemistry (2012) 55 (3036-3048) DOI:10.1021/jm201386u);Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1 H -indol-2-yl)-2- (trifluoromethyl)-4,7-dihydropyrazolo[1,5- a ]pyrimidin-6-yl)((S)-2-(3- methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I Kur inhibitor

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3036-3048

  Finlay, Heather J ^a   Lloyd, John ^a   Vaccaro, Wayne ^a   Kover, Alexander ^a   Yan, Lin ^a   Bhave, Gauri ^a   Prol, Joseph ^a   Huynh, Tram ^a   Bhandaru, Rao ^a   Caringal, Yolanda ^a   Dimarco, John ^a   Gan, Jinping ^a   Harper, Tim ^a   Huang, Christine ^a   Conder, Mary Lee ^a   Sun, Huabin ^a   Levesque, Paul ^a   Blanar, Michael ^a   Atwal, Karnail ^a   Wexler, Ruth ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3,4 DICHLOROPHENYL) ETHYLIDENE] 1 (4 PHENYLPIPERAZIN 1 YL) BUTANE 1,3 DIONE; 3 CHLORO 1H PYRAZOL 5 AMINE; 3 METHYL 5 (PYRROLIDIN 2 YL) ISOXAZOLE; 4 (TERT BUTOXYCARBONYL) 2 CYCLOPROPYL 7 (3,4 DICHLOROPHEN YL) 5 METHYL 4,7 DIHYDROPYRAZONOL (1,5 ALPHA) PYRAMIDINE 6 CARBOXYLIC ACID; 4 (TERT BUTOXYCARBONYL) 5 (METHOXYMETHYL) 7 (METHYL 1H INDOLE 2 YL) 2 (TRIFLUOROMETHYL) 4,7 DIHYDROPYRAZONOL (1,5 ALPHA) PYRAMIDINE 6 CARBOXYLIC ACID; 4 (TERT BUTOXYCARBONYL) 5 METHYL 7 [1 METHYL 1H BENZO (DEXTRO) IMIDAZOL 2 YL] 2 (TRIFLUOROMETHYL) 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PNYRAMIDINE 6 CARBOXYLIC ACID; 4 (TERT BUTOXYCARBONYL) 5METHYL 7 (1 METHYL 1H INDOL 2 YL) 2 (TRIFLUOROMETHYL) 4,7 DIHYDROPYRAZONOL (1,5 ALPHA) PYRAMIDINE 6 CARBOXYLIC ACID; 4 (TERT BUTOXYCARBONYL) 7 (3,4 DICHLOROPHENYL) 2 5 DIMETHYL 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 5 CARBOXYLIC ACID; 7 [BENZO (DEXTRO) THIAZOL 2 YL) 4 (TERT BUTOXYCARBONYL) 5 METHYL 2 (TRIFLUOROMETHYL) 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRAMIDINE 6 CARBOXYLIC ACID; GLUTATHIONE; ION CHANNEL; POTASSIUM CHANNEL; PYRAZOLOPYRIMIDINE DERIVATIVE; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; UNINDEXED DRUG; [2 CHLORO 7 (3,4 DICHLOROPHENYL) 5 METHYL 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6YL] (6 PHENYLPIPERAZIN 1 YL) METHANONE; [2 CYCLOPROPYL 7 (3,4 DICHLOROPHEN YL) 5 METHYL 4,7 DIHYDROPYRAZONOL (1,5 ALPHA) PYRAMIDINE 6 YL] [2 (3 METHYLISOXAZOL 5 YL) PYRROLIDIN 1 YL] METHANONE; [3 CHLORO 7 (3,4 DICHLOROPHENYL) 5 METHYL 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] [4 (4 FLUOROPHENYL) PIPERAZIN 1 YL] METHANONE; [5 (METHOXYMETHYL) 7 (1 METHYL 1 HINDOL 2 YL) 2 (TRIFLUOROMETHYL) 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] [2 (3 METHYLISOXAZOL 5 YL) PYRROLIDIN 1 YL] METHANONE; [5 METHYL 7 [1 METHYL 1H BENZO (DEXTRO) IMIDAZOL 2 YL] 2 (TRIFLUOROMETHYL) 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRAMIDIN 6 YL] [2 3 (METHYLISOXAZOL 5 YL) PYRROLIDIN 1 YL] METHANONE; [7 (3,4 DICHLOROPHENYL) 2 5 DIMETHYL 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] [2 (4 FLUOROPHENYL) PYRROLIDIN 1 YL] METHANONE; [7 (3,4 DICHLOROPHENYL) 2,5 DIMETHYL 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] (4 PHENYLPIPERAZIN 1 YL) METHANONE; [7 (3,4 DICHLOROPHENYL) 2,5 DIMETHYL 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] [2 (3 METHYLISOXAZOL 5 YL) PYRROLIDIN 1 YL] METHANONE; [7 (3,4 DICHLOROPHENYL) 3 5 DIMETHYL 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] [2 (4 FLUOROPHENYL) PYRROLIDIN 1 YL] METHANONE; [7 (3,4 DICHLOROPHENYL) 5 (METHOXYMETHYL) 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] [2 (3 METHYLISOXAZOL 5 YL) PYRROLIDIN 1 YL] METHANONE; [7 (3,4 DICHLOROPHENYL) 5 METHYL 2 (TRIFLUOROMETHYL) 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] (4 PHENYLPIPERAZIN 1 YL) METHANONE; [7 (3,4 DICHLOROPHENYL) 5 METHYL 2 (TRIFLUOROMETHYL) 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] [2 (3 METHYLISOXAZOL 5 YL) PYRROLIDIN 1 YL] METHANONE; [7 (3,4 DICHLOROPHENYL) 5 METHYL 2 (TRIFLUOROMETHYL) 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] [2 (4 FLUOROPHENYL) PYRROLIDIN 1 YL] METHANONE; [7 (3,4 DICHLOROPHENYL) 5 METHYL 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] [2 (3 METHYLISOXAZOL 5 YL) PYRROLIDIN 1 YL] METHANONE; [7 [BENZO (DEXTRO) THIAZOL 2 YL] 5 METHYL 2 (TRIFLUOROMETHYL) 4,7 DIHYDROPYRAZOLO (1,5 ALPHA) PYRIMIDIN 6 YL] [2 (3 METHYLISOXAZOL 5 YL) PYRROLIDIN 1 YL] METHANONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIAL EFFECTIVE REFRACTORY PERIOD; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SYNTHESIS; HEART DISEASE; NONHUMAN; POTASSIUM CURRENT; RABBIT; RAT;

EID: 84859789514     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4010576     Document Type: Erratum

References (24)

1. Go, A.; Hylek, E.; Phillips, K.; Chang, Y.; Henault, L.; Selby, J.; Singer, D. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA, J. Am. Med. Assoc. 2001, 285, 2370-2375
2. Miyasaka, Y.; Barnes, M. E.; Gersh, B. J.; Cha, S. S.; Bailey, K. R.; Abhayaratna, W. P.; Seward, J. B.; Tsang, T. S. M. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 2006, 114, 119-125
3. Hart, R. G.; Halperin, J. L. Atrial fibrillation and stroke: concepts and controversies Stroke 2001, 32, 803-808
4. Janko, S.; Dorwarth, U.; Hoffmann, E. Pharmacotherapy of atrial fibrillation: an old option with new possibilities Expert Opin. Pharmacother. 2008, 9, 913-925
5. Sven, K.; Dierk, T.; Karle, C. A. The novel antiarrhythmic drug dronedarone: comparison with amiodarone Cardiovasc. Drug Rev. 2005, 23, 217-230
6. Chong, P. H.; Cory, F.; Yim, B. T. Treatment of Atrial Fibrillation and Flutter: Focus on Oral Dofetilide, a New Selective Class III Antiarrhythmic Agent HeartDrug 2001, 1, 320-331
7. Wang, Z.; Page, P.; Nattel, S. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation Circ. Res. 1992, 71, 271-287
8. Hohnloser, S. H.; van de Loo, A.; Baedeker, F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine J. Am. Coll. Cardiol. 1995, 26, 852-858
9. De Bruin, M. L.; Hoes, A. W.; Leufkens, H. G. QTc-Prolonging Drugs and Hospitalizations for Cardiac Arrhythmias Am. J. Cardiol. 2003, 91, 59-62
10. Nattel, S. New ideas about atrial fibrillation 50 years on Nature 2002, 415, 219-226
11. Ford, J. W.; Milnes, J. T. New Drugs Targeting the Cardiac Ultra-Rapid Delayed-Rectifier Current (IKur): Rationale, Pharmacology and Evidence for Potential Therapeutic Value J. Cardiovasc. Pharmacol. 2008, 52 (2) 105-120
12. Lloyd, J; Finlay, H. J.; Atwal, K; Kover, A; Prol, J; Yan, L; Bhandaru, R; Vaccaro, W; Huynh, T; Huang, C. S.; Conder, M; Jenkins-West, T; Sun, H; Li, D; Levesque, P. Dihydropyrazolopyrimidines containing benzimidazoles as KV1.5 potassium channel antagonists Bioorg. Med. Chem. Lett. 2009, 19 (18) 5469-5473
13. Lloyd, J; Finlay, H. J.; Vacarro, W; Hyunh, T; Kover, A; Bhandaru, R; Yan, L; Atwal, K; Conder, M; Jenkins-West, T; Shi, H.; Huang, C; Li, D; Sun, H; Levesque, P. Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers Bioorg. Med. Chem. Lett. 2010, 20 (4) 1436-1439
14. Vacarro, W.; Huynh, T.; Lloyd, J.; Atwal, K. S.; Finlay, H. J.; Levesque, P. C.; Conder, M. L.; Jenkins-West, T.; Shi, H.; Sun, L. Dihydropyrazolopyrimidine inhibitors of KV1.5 (I Kur) Bioorg. Med. Chem. Lett. 2008, I18 (24) 6381-6385
15. Treiber, A.; Dansette, P. M.; Hamid, E.; Girault, J.-P.; Ginderow, D.; Mornon, J.-P.; Mansuy, D. Chemical and Biological Oxidation of Thiophene: Preparation and Complete Characterization of Thiophene S -Oxide Dimers and Evidence for Thiophene S -Oxide as an Intermediate in Thiophene Metabolism in Vivo and in Vitro J. Am. Chem. Soc. 1997, 119, 1565-1571
16. Nassar, A. F.; Lopez-Anaya, A. Strategies for dealing with reactive intermediates in drug discovery and development Curr. Opin. Drug Discovery Dev. 2004, 7, 126-136
17. Reimlinger, H.; Van Overstraeten, A. Reactions of 3(5)-diazopyrazole. II Chem. Ber. 1966, 99, 3350-3357
18. Kirk, K. L.; Cohen, L. A. Photochemistry of diazonium salts. I. Synthesis of 4-fluoroimidazoles, 4-fluorohistamine, and 4-fluorohistidine J. Am. Chem. Soc. 1973, 95, 4619-4624
19. Janssen, J. W. A. M.; Koeners, H. J.; Kruse, C. G.; Habraken, C. L. Pyrazoles. XII. Preparation of 3(5)-nitropyrazoles by thermal rearrangement of N -nitropyrazoles J. Org. Chem. 1973, 38, 1777-1782
20. Garvey, D. S.; Wasicak, J. T.; Elliott, R. L.; Lebold, S.; Hettinger, A.; Carrera, G. M.; Lin, N.; He, Y.; Holladay, M. W. Ligands for Brain Cholinergic Channel Receptors: Synthesis and in Vitro Characterization of Novel Isoxazoles and Isothiazoles as Bioisosteric Replacements for the Pyridine Ring in Nicotine J. Med. Chem. 1994, 37 (26) 4455-4463
21. Synders, D. J.; Tamakun, M. N.; Bennett, P. B. A rapidly activating and slowly inactivating potassium channel cloned from human heart: functional analysis after stable mammalian cell culture expression J. Gen. Physiol. 1993, 101, 513-543
22. Zhou, Z.; Vorperian, V. R.; Gong, Q.; Zhang, S. and January, C.T. Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole J. Cardiovasc. Electrophysiol. 1999, 10 (6) 836-843
23. Li, D.; Sun, H.; Levesque, P. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety Cardiovasc. Hematol. Agents Med. Chem. 2009, 7 (1) 64-75
24. Carlsson, Leif. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes Pharmacol. Ther. 2008, 119 (2) 160-167